Unit:
Faculty of MedicineLibrary of the School of Health Sciences
Author:
Kontaxakis Anastasios
Dissertation committee:
Παπακωνσταντίνου Δημήτριος, Καθηγητής , Ιατρική Σχολή, ΕΚΠΑ
Κουτσανδρέα Χρυσάνθη, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Γεωργάλας Ηλίας, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κυμιωνής Γεώργιος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Χατζηστεφάνου Κλειώ, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Δρούτσας Κωννσταντίνος, Επίκουρος Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Χατζηράλλη Ειρήνη, Επίκουρη Καθηγήτρια Οφθαλμολογίας, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Μετεγχειρητική παρακολούθηση μορφολογίας διηθητικής φυσαλίδας σε ασθενείς που υποβλήθηκαν σε τραμπεκουλεκτομία
Translated title:
Postoperative follow-up of bleb morphology in patients recruited for primary trabeculectomy
Summary:
Purpose: The aim of this study was to determine whether glaucoma patients after trabeculectomy could benefit more from subconjunctival injections of bevacizumab than 5-FU or placebo.Methods and results: Fifty-one eyes of 51 patients were recruited for primary MMC (0.2 mg/mL for 1 min) augmented trabeculectomy. 17 patients were randomly assigned to receive 1.25 mg (0.05 mL) of bevacizumab augmentation, 21 patients were assigned to receive 0.1 mL of 50 mg/mL 5-FU and 13 patients were assigned to a control group receiving a normal saline injection as a placebo. Initial recruitment included 58 patients, but seven patients had to be excluded from the study for various reasons. Postoperative follow up of IOP and bleb characteristics was carried out at 1 day, 1 week,3 weeks, 6 weeks, 6 months and 1 year after surgery. All analyses where carried out by two masked clinicians. IOP reduction was statistically significant (p < 0.05) across all three groups between baseline visit and final 1-year postoperative visit. There was no significant difference of the final average IOP val- ues between the three groups. Bleb evaluation was made using the Moorfields bleb grading system (MBGS) after 1 year follow up. Central bleb area was statistically greater in the Bevacizumab group when compared with the 5-FU group but not with the placebo group. The vascularity of the central bleb was significantly different between the groups with the Bevacizumab group showing the least vascularity. Vascularity of the peripheral bleb was also decreased in the Bevacizumab group when com- pared with the placebo group but not with the 5-FU group.Conclusion: The 12-month IOP results showed no significant differences between the groups of patients after Bevacizumab, 5-FU or placebo to augment primary MMC enhanced trabeculectomy. However, by the analysis of bleb morphology there was a significant difference in terms of central bleb area and vascularity.
Main subject category:
Health Sciences
Keywords:
Trabeculectomy, Bleb morphology, Bevacizumab, Trabeculectomy and bevacizumab, Bleb vascularity
Number of references:
323
File:
File access is restricted only to the intranet of UoA.
Kontaxakis_Anastasios_PhD.pdf.pdf
6 MB
File access is restricted only to the intranet of UoA.
